Boston Scientific (BSX) to Release Earnings on Wednesday

Boston Scientific (NYSE:BSX) is anticipated to post its Q4 2025 results before the market opens on Wednesday, February 4th. Analysts expect Boston Scientific to post earnings of $0.78 per share and revenue of $5.2896 billion for the quarter. Parties may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Wednesday, February 4, 2026 at 8:00 AM ET.

Boston Scientific Stock Up 0.1%

BSX stock opened at $93.63 on Wednesday. Boston Scientific has a 52 week low of $85.98 and a 52 week high of $109.50. The business has a 50-day simple moving average of $95.42 and a 200 day simple moving average of $99.69. The company has a quick ratio of 0.96, a current ratio of 1.51 and a debt-to-equity ratio of 0.47. The company has a market cap of $138.81 billion, a PE ratio of 50.07, a price-to-earnings-growth ratio of 1.70 and a beta of 0.67.

Insider Activity at Boston Scientific

In related news, Director Ellen M. Zane sold 12,891 shares of the business’s stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $98.28, for a total transaction of $1,266,927.48. Following the sale, the director owned 24,134 shares in the company, valued at $2,371,889.52. The trade was a 34.82% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $101.55, for a total value of $1,758,135.15. Following the completion of the transaction, the executive vice president owned 23,600 shares of the company’s stock, valued at $2,396,580. This represents a 42.32% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 80,204 shares of company stock valued at $7,998,563 in the last 90 days. 0.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Boston Scientific

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Marshall Wace LLP raised its stake in shares of Boston Scientific by 30.7% during the third quarter. Marshall Wace LLP now owns 9,799,040 shares of the medical equipment provider’s stock valued at $956,680,000 after acquiring an additional 2,301,383 shares during the last quarter. Credit Agricole S A acquired a new stake in Boston Scientific in the third quarter valued at $204,812,000. Amundi raised its position in Boston Scientific by 17.5% during the 3rd quarter. Amundi now owns 11,981,584 shares of the medical equipment provider’s stock worth $1,158,619,000 after purchasing an additional 1,781,830 shares during the last quarter. Man Group plc lifted its holdings in Boston Scientific by 79.8% during the 3rd quarter. Man Group plc now owns 3,843,937 shares of the medical equipment provider’s stock worth $375,284,000 after buying an additional 1,706,494 shares during the period. Finally, Raymond James Financial Inc. grew its position in shares of Boston Scientific by 32.8% in the 3rd quarter. Raymond James Financial Inc. now owns 3,157,207 shares of the medical equipment provider’s stock valued at $308,237,000 after buying an additional 779,938 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on BSX shares. UBS Group restated a “buy” rating on shares of Boston Scientific in a research report on Wednesday, December 17th. Erste Group Bank downgraded shares of Boston Scientific from a “buy” rating to a “hold” rating in a research report on Friday, October 3rd. Wall Street Zen upgraded Boston Scientific from a “hold” rating to a “buy” rating in a research note on Saturday, January 17th. Truist Financial decreased their price target on Boston Scientific from $130.00 to $120.00 and set a “buy” rating on the stock in a research note on Thursday, December 18th. Finally, BTIG Research restated a “buy” rating and set a $132.00 price objective on shares of Boston Scientific in a research report on Friday, November 21st. One research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, Boston Scientific currently has an average rating of “Moderate Buy” and a consensus price target of $123.89.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.